The selective mu-opioid receptor antagonist ADL5510 reduces levodopa-induced dyskinesia without affecting antiparkinsonian action in MPTP-lesioned macaque model of Parkinson's disease (Q42486325)

From Wikidata

Jump to navigation Jump to search

scientific article published on 4 April 2011

Language	Label	Description	Also known as
English	The selective mu-opioid receptor antagonist ADL5510 reduces levodopa-induced dyskinesia without affecting antiparkinsonian action in MPTP-lesioned macaque model of Parkinson's disease	scientific article published on 4 April 2011

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

1 November 2017

The selective mu-opioid receptor antagonist ADL5510 reduces levodopa-induced dyskinesia without affecting antiparkinsonian action in MPTP-lesioned macaque model of Parkinson's disease (English)

1 reference

Europe PubMed Central

PubMed publication ID

1 November 2017

0 references

Parkinson's disease

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

0 references

Tom H. Johnston

3

1 reference

Europe PubMed Central

PubMed publication ID

1 November 2017

Jonathan M. Brotchie

object named as

Jonathan M Brotchie

10

0 references

2

object named as

Susan H Fox

1 reference

Europe PubMed Central

PubMed publication ID

1 November 2017

James B Koprich

1

object named as

James B Koprich

1 reference

Europe PubMed Central

PubMed publication ID

1 November 2017

author name string

Allan Goodman

4

1 reference

Europe PubMed Central

PubMed publication ID

1 November 2017

Bertrand Le Bourdonnec

5

1 reference

Europe PubMed Central

PubMed publication ID

1 November 2017

Roland E Dolle

6

1 reference

Europe PubMed Central

PubMed publication ID

1 November 2017

Robert N DeHaven

7

1 reference

Europe PubMed Central

PubMed publication ID

1 November 2017

Diane L DeHaven-Hudkins

8

1 reference

Europe PubMed Central

PubMed publication ID

1 November 2017

Patrick J Little

9

1 reference

Europe PubMed Central

PubMed publication ID

1 November 2017

language of work or name

0 references

publication date

4 April 2011

1 reference

Europe PubMed Central

PubMed publication ID

1 November 2017

Movement Disorders

1 reference

Europe PubMed Central

PubMed publication ID

1 November 2017

26

1 reference

Europe PubMed Central

PubMed publication ID

1 November 2017

7

1 reference

Europe PubMed Central

PubMed publication ID

1 November 2017

1225-1233

1 reference

Europe PubMed Central

PubMed publication ID

1 November 2017

Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa

1 reference

https://api.crossref.org/works/10.1002%2FMDS.23631

21 January 2018

Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD.

1 reference

https://api.crossref.org/works/10.1002%2FMDS.23631

21 January 2018

A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa

1 reference

https://api.crossref.org/works/10.1002%2FMDS.23631

21 January 2018

Sydney Multicenter Study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years

1 reference

https://api.crossref.org/works/10.1002%2FMDS.23631

21 January 2018

Evolution of striatal opiate receptors

1 reference

https://api.crossref.org/works/10.1002%2FMDS.23631

21 January 2018

Pathophysiology of levodopa-induced dyskinesia: potential for new therapies

1 reference

https://api.crossref.org/works/10.1002%2FMDS.23631

21 January 2018

A hypothesis on the pathophysiological mechanisms that underlie levodopa- or dopamine agonist-induced dyskinesia in Parkinson's disease: implications for future strategies in treatment

1 reference

https://api.crossref.org/works/10.1002%2FMDS.23631

21 January 2018

Neuronal activity in the globus pallidus in chorea caused by striatal lacunar infarction

1 reference

https://api.crossref.org/works/10.1002%2FMDS.23631

21 January 2018

Common neural mechanisms in experimental chorea and hemiballismus in the monkey. Evidence from 2-deoxyglucose autoradiography

1 reference

https://api.crossref.org/works/10.1002%2FMDS.23631

21 January 2018

Internal globus pallidus discharge is nearly suppressed during levodopa-induced dyskinesias

1 reference

https://api.crossref.org/works/10.1002%2FMDS.23631

21 January 2018

Cortical motor overactivation in parkinsonian patients with L-dopa-induced peak-dose dyskinesia.

1 reference

https://api.crossref.org/works/10.1002%2FMDS.23631

21 January 2018

Neuronal activity in the basal ganglia in patients with generalized dystonia and hemiballismus.

1 reference

https://api.crossref.org/works/10.1002%2FMDS.23631

21 January 2018

Effect of repeated L-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat.

1 reference

https://api.crossref.org/works/10.1002%2FMDS.23631

21 January 2018

Increased striatal pre-proenkephalin B expression is associated with dyskinesia in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1002%2FMDS.23631

21 January 2018

Ropinirole versus L-DOPA effects on striatal opioid peptide precursors in a rodent model of Parkinson's disease: implications for dyskinesia

1 reference

https://api.crossref.org/works/10.1002%2FMDS.23631

21 January 2018

Enhanced preproenkephalin-B-derived opioid transmission in striatum and subthalamic nucleus converges upon globus pallidus internalis in L-3,4-dihydroxyphenylalanine-induced dyskinesia.

1 reference

https://api.crossref.org/works/10.1002%2FMDS.23631

21 January 2018

Alterations in cortical and basal ganglia levels of opioid receptor binding in a rat model of l-DOPA-induced dyskinesia

1 reference

https://api.crossref.org/works/10.1002%2FMDS.23631

21 January 2018

Mu- and delta-opioid receptor antagonists reduce levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1002%2FMDS.23631

21 January 2018

Alterations in opioid receptor binding in Parkinson's disease patients with levodopa-induced dyskinesias

1 reference

https://api.crossref.org/works/10.1002%2FMDS.23631

21 January 2018

Non-subtype-selective opioid receptor antagonism in treatment of levodopa-induced motor complications in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1002%2FMDS.23631

21 January 2018

High dose naltrexone for dyskinesias induced by levodopa

1 reference

https://api.crossref.org/works/10.1002%2FMDS.23631

21 January 2018

Naltrexone, an opiate antagonist, fails to modify motor symptoms in patients with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1002%2FMDS.23631

21 January 2018

Naltrexone in the short-term decreases antiparkinsonian response to l-Dopa and in the long-term increases dyskinesias in drug-naïve parkinsonian monkeys

1 reference

https://api.crossref.org/works/10.1002%2FMDS.23631

21 January 2018

Dyskinesias occur in response to saline and naltrexone alone after priming with combination of dopaminergic agents and naltrexone in the MPTP parkinsonian monkeys

1 reference

https://api.crossref.org/works/10.1002%2FMDS.23631

21 January 2018

Opioid antagonists increase the dyskinetic response to dopaminergic agents in parkinsonian monkeys: interaction between dopamine and opioid systems

1 reference

https://api.crossref.org/works/10.1002%2FMDS.23631

21 January 2018

The opioid agonist morphine decreases the dyskinetic response to dopaminergic agents in parkinsonian monkeys

1 reference

https://api.crossref.org/works/10.1002%2FMDS.23631

21 January 2018

Reduction of L-DOPA-induced dyskinesia by the selective metabotropic glutamate receptor 5 antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1002%2FMDS.23631

21 January 2018

Control of glutamate release by calcium channels and kappa-opioid receptors in rodent and primate striatum

1 reference

https://api.crossref.org/works/10.1002%2FMDS.23631

21 January 2018

Presynaptic kappa-opioid and muscarinic receptors inhibit the calcium-dependent component of evoked glutamate release from striatal synaptosomes

1 reference

https://api.crossref.org/works/10.1002%2FMDS.23631

21 January 2018

Topiramate reduces levodopa-induced dyskinesia in the MPTP-lesioned marmoset model of Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1002%2FMDS.23631

21 January 2018

A kappa opioid antagonist blocks sensitization in a rodent model of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1002%2FMDS.23631

21 January 2018

Levodopa-induced dyskinesias

1 reference

https://api.crossref.org/works/10.1002%2FMDS.23631

21 January 2018

Levodopa-induced dyskinesia in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1002%2FMDS.23631

21 January 2018

Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations

1 reference

https://api.crossref.org/works/10.1002%2FMDS.23631

21 January 2018

Early treatment benefits of ropinirole prolonged release in Parkinson's disease patients with motor fluctuations

1 reference

https://api.crossref.org/works/10.1002%2FMDS.23631

21 January 2018

Tesofensine (NS 2330), a monoamine reuptake inhibitor, in patients with advanced Parkinson disease and motor fluctuations: the ADVANS Study

1 reference

https://api.crossref.org/works/10.1002%2FMDS.23631

21 January 2018

A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease

1 reference

https://api.crossref.org/works/10.1002%2FMDS.23631

21 January 2018

Levodopa-induced dyskinesias improved by a glutamate antagonist in Parkinsonian monkeys

1 reference

https://api.crossref.org/works/10.1002%2FMDS.23631

21 January 2018

CB1 cannabinoid receptor signalling in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1002%2FMDS.23631

21 January 2018

Development of dyskinesias in a 5-year trial of ropinirole andL-dopa

1 reference

https://api.crossref.org/works/10.1002%2FMDS.23631

21 January 2018

Identifiers

10.1002/MDS.23631

1 reference

Europe PubMed Central

PubMed publication ID

1 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

1 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42486325&oldid=1959094205"